A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

Inclusion Criteria

• •Participant must be healthy, without significant medical illness, on the basis of physical examination, medical history, and vital signs performed at screening
• •Participant must be healthy on the basis of clinical laboratory tests performed at screening. If the results of the laboratory screening tests are outside the laboratory normal reference ranges, and additionally within the limits representing Food and Drug Administration (FDA) toxicity Grade 1, the participant may be considered eligible only if the investigator judges the abnormalities or deviations from normal to be not clinically significant and reasonable for the population under study. This determination must be recorded in the participant's source documents and initialed by the investigator
• •Participant must agree not to donate bone marrow, blood, and blood products from the first study vaccine administration until 3 months after the last study vaccine administration
• •Participant must be willing to provide verifiable identification
• •All female participants of childbearing potential must have:
• •1. a negative serum beta human chorionic gonadotropin (beta-hCG) pregnancy test at screening
• •2. a negative urine (beta-hCG) pregnancy test immediately prior to each study vaccine administration